BMT CTN Protocol 1102

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome.

Below are protocol-related documents, which may be periodically updated.

• Protocol Synopsis, 5.0 dated November 28, 2018
• Protocol, 5.0 dated November 28, 2018
• Summary of Changes from version 4.0 to version 5.0
• Informed Consent, 4.0 dated July 2, 2015
• Frequently Asked Questions
• This study is posted on clinicaltrials.gov as NCT02016781.
• Key Personnel

            Protocol Co-Chair: Ryotaro Nakamura, MD (626-256-4673) rnakamura@coh.org

            Protocol Co-Chair: Corey Cutler,MD () cscutler@partners.org

            Protocol Officer: Wael Saber, MD414-805-0300) wsaber@mcw.edu

            Protocol Coordinators: Alyssa Ramirez (301-251-1161) aramirez@emmes.com

                                                    Garett Skelton bmtctn1102@emmes.com

            Medical Monitor: Bipin Savini, MD bipin.savini@vanderbilt.edu

                   

The BMT CTN is committed to including widespread transplant community participation in these trials. However, affiliate center applications are not currently being accepted for this study.